中國北大荒(00039.HK)擬與頤詩康特建立電商平台銷售食品及酒類
格隆匯5月27日丨中國北大荒(00039.HK)發佈公吿,2021年5月27日,公司與頤詩康特健康管理有限公司(“頤詩康特”)訂立戰略合作框架協議,內容有關建議建立電商平台,並透過該平台銷售食品及酒類。
根據框架協議,訂約方須利用各自的優勢,並在產業與資本融合發展的理念上合作。訂約方同意在深圳共同成立一間有限公司,註冊資本為人民幣1000萬元,作為戰略合作的項目實體。公司及頤詩康特於項目公司的股權將分別為60%及40%;頤詩康特將負責為項目公司開發該平台,並組織線上及線下銷售團隊,旨在透過該平台達到年度銷售額人民幣40億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.